No Data
Awakn Announces Opening of Four Additional AWKN-001 Phase 3 Trial Sites
Awakn Partners With University Of Nottingham For Preclinical Testing Of Psychoactive Therapy
Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program
Investors Back Awakn's Psychedelic Therapies, As Company Doubles Private Placement To $2M
Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program
Awakn Life Sciences Provides Update on Aminoindane New Chemical Entity Patent Portfolio
No Data